{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:24:54Z","timestamp":1791897894071,"version":"4.3.4"},"reference-count":243,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374050"],"award-info":[{"award-number":["82374050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.apsb.2025.10.019","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T04:08:43Z","timestamp":1761365323000},"page":"169-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunocyte reprogramming empowers live-cell drug delivery: Mechanistic insights, delivery strategies, and clinical perspectives"],"prefix":"10.1016","volume":"16","author":[{"given":"Zheng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-9013","authenticated-orcid":false,"given":"Chengcheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonggao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingpeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.10.019_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jconrel.2020.07.043","article-title":"Immune cells as tumor drug delivery vehicles","volume":"327","author":"Combes","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/ni1275","article-title":"Immune cell migration in inflammation: present and future therapeutic targets","volume":"6","author":"Luster","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/imr.12757","article-title":"Exploring the complex role of chemokines and chemoattractants in vivo on leukocyte dynamics","volume":"289","author":"David","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apsb.2025.10.019_bib4","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1158\/0008-5472.CAN-18-1367","article-title":"Diverse functions of macrophages in different tumor microenvironments","volume":"78","author":"Yang","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.019_bib5","article-title":"Immune response recalibration using immune therapy and biomimetic nano-therapy against high-grade gliomas and brain metastases","volume":"20","author":"Sandhbor","year":"2025","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib7","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1021\/acs.nanolett.8b01236","article-title":"Bioengineered macrophages can responsively transform into nanovesicles to target lung metastasis","volume":"18","author":"Cao","year":"2018","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2025.10.019_bib8","article-title":"Metabolic reprogramming of immune cells in the tumor microenvironment","volume":"25","author":"Wang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jconrel.2021.11.016","article-title":"Nano-engineered immune cells as \"guided missiles\" for cancer therapy","volume":"341","author":"Zhang","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1749-6632.2012.06508.x","article-title":"Reprogramming cell fates: insights from combinatorial approaches","volume":"1266","author":"Pereira","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib11","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.3389\/fimmu.2019.02809","article-title":"Understanding and modulating immunity with cell reprogramming","volume":"10","author":"Pires","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107603","article-title":"Genetically modified immune cells targeting tumor antigens","volume":"214","author":"Poorebrahim","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2025.10.019_bib13","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.2147\/IJN.S110146","article-title":"Nanomedicine engulfed by macrophages for targeted tumor therapy","volume":"11","author":"Li","year":"2016","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.10.019_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2023.114840","article-title":"Engineering cells for precision drug delivery: new advances, clinical translation, and emerging strategies","volume":"197","author":"Chao","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.10.019_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/10717544.2016.1230903","article-title":"A novel strategy to achieve effective drug delivery: exploit cells as carrier combined with nanoparticles","volume":"24","author":"Pang","year":"2017","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2025.10.019_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2025.10.019_bib17","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1016\/j.apsb.2024.04.034","article-title":"Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells","volume":"14","author":"Tang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.019_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2025.10.019_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/HM9.0000000000000032","article-title":"Nature products of traditional Chinese medicine provide new ideas in \u03b3\u03b4T cell for tumor immunotherapy","volume":"2","author":"Duya","year":"2022","journal-title":"Acupuncture and Herbal Medicine"},{"key":"10.1016\/j.apsb.2025.10.019_bib20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s004180000224","article-title":"Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer","volume":"115","author":"Kuppen","year":"2001","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.apsb.2025.10.019_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006401","article-title":"Barriers to immune cell infiltration in tumors","volume":"11","author":"Melssen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.10.019_bib22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jconrel.2024.09.037","article-title":"New avenues for cancer immunotherapy: cell-mediated drug delivery systems","volume":"375","author":"Zhang","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","article-title":"Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo","volume":"350","author":"Zhou","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/cell.2022.0047","article-title":"The tumor microenvironment reprograms immune cells","volume":"24","author":"Cao","year":"2022","journal-title":"Cell Reprogr"},{"key":"10.1016\/j.apsb.2025.10.019_bib25","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1080\/10717544.2020.1831103","article-title":"Cell-mediated targeting drugs delivery systems","volume":"27","author":"Yu","year":"2020","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2025.10.019_bib26","first-page":"55","article-title":"Macrophage based drug delivery: key challenges and strategies","volume":"38","author":"Guo","year":"2024","journal-title":"Bioact Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib27","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1002\/smll.201601282","article-title":"Macrophages as active nanocarriers for targeted early and adjuvant cancer chemotherapy","volume":"12","author":"Si","year":"2016","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.10.019_bib28","doi-asserted-by":"crossref","first-page":"13894","DOI":"10.1021\/acsnano.0c06290","article-title":"A smart nanoparticle-laden and remote-controlled self-destructive macrophage for enhanced chemo\/chemodynamic synergistic therapy","volume":"14","author":"Sun","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.019_bib29","doi-asserted-by":"crossref","first-page":"H105","DOI":"10.1002\/adma.201004074","article-title":"Cell-based drug delivery devices using phagocytosis-resistant backpacks","volume":"23","author":"Doshi","year":"2011","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-0716-0203-4_1","article-title":"T cell reprogramming against cancer","volume":"2097","author":"Katz","year":"2020","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.apsb.2025.10.019_bib31","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1016\/j.apsb.2025.07.007","article-title":"Nanomedicine strategies for cuproptosis: metabolic reprogramming and tumor immunotherapy","volume":"15","author":"Zhang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.019_bib32","article-title":"CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines","volume":"6","author":"Look","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.apsb.2025.10.019_bib33","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021109353","article-title":"Elp3-mediated codon-dependent translation promotes mTORC2 activation and regulates macrophage polarization","volume":"41","author":"Chen","year":"2022","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2025.10.019_bib34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2025.10.019_bib35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2025.10.019_bib36","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nm.4356","article-title":"Elimination of large tumors in mice by mRNA-encoded bispecific antibodies","volume":"23","author":"Stadler","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.10.019_bib37","doi-asserted-by":"crossref","first-page":"8658","DOI":"10.1038\/s41467-024-52666-y","article-title":"GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency","volume":"15","author":"Guerrero","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.019_bib38","first-page":"35","article-title":"Targeting metabolic reprogramming of T-cells for enhanced anti-tumor response","volume":"16","author":"Dabi","year":"2022","journal-title":"Biologics"},{"key":"10.1016\/j.apsb.2025.10.019_bib39","article-title":"Artificially reprogrammed macrophages as tumor-tropic immunosuppression-resistant biologics to realize therapeutics production and immune activation","volume":"31","author":"Li","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40824-023-00350-5","article-title":"Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment","volume":"27","author":"Zheng","year":"2023","journal-title":"Biomater Res"},{"key":"10.1016\/j.apsb.2025.10.019_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119498","article-title":"An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy","volume":"586","author":"Song","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2025.10.019_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113068","article-title":"Hypoxia, a key factor in the immune microenvironment","volume":"151","author":"Hu","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.10.019_bib43","doi-asserted-by":"crossref","first-page":"9783","DOI":"10.1007\/s11033-022-07474-2","article-title":"Immune cell metabolism and metabolic reprogramming","volume":"49","author":"Hu","year":"2022","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.apsb.2025.10.019_bib44","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/cells11050768","article-title":"New immunometabolic strategy based on cell type-specific metabolic reprogramming in the tumor immune microenvironment","volume":"11","author":"Sung","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2025.10.019_bib45","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cmet.2018.08.009","article-title":"The translational machinery of human CD4+ T cells is poised for activation and controls the switch from quiescence to metabolic remodeling","volume":"28","author":"Ricciardi","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2025.10.019_bib46","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.10.019_bib47","article-title":"Innate immune cells in oral squamous cell carcinoma: characteristics and therapeutic potential","volume":"6","author":"Jiang","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.apsb.2025.10.019_bib48","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/gt.2008.38","article-title":"Cell vehicle targeting strategies","volume":"15","author":"Roth","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2025.10.019_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114233","article-title":"Immunoengineering strategies to enhance vascularization and tissue regeneration","volume":"184","author":"Zarubova","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.10.019_bib50","article-title":"Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy","volume":"36","author":"Metzloff","year":"2024","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib51","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s44222-024-00193-2","article-title":"Engineered polysaccharides for controlling innate and adaptive immune responses","volume":"2","author":"Nam","year":"2024","journal-title":"Nat Rev Bioeng"},{"key":"10.1016\/j.apsb.2025.10.019_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2022038827","article-title":"An overview on macrophage targeting: a promising approach","volume":"40","author":"Vemuri","year":"2023","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.apsb.2025.10.019_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202002054","article-title":"Engineering macrophages for cancer immunotherapy and drug delivery","volume":"32","author":"Xia","year":"2020","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib54","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3390\/pharmaceutics15102458","article-title":"Immunoengineering via chimeric antigen receptor-T cell therapy: reprogramming nanodrug delivery","volume":"15","author":"Katopodi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.019_bib55","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s12951-024-02746-4","article-title":"Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery","volume":"22","author":"McCrlean","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2025.10.019_bib56","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12951-022-01526-2","article-title":"Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer","volume":"20","author":"Zhao","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2025.10.019_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108164","article-title":"Macrophages mediated delivery of chlorin e6 and treatment of lung cancer by photodynamic reprogramming","volume":"100","author":"Yu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2025.10.019_bib58","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/cancers16020435","article-title":"Small molecule immunomodulators as next-generation therapeutics for glioblastoma","volume":"16","author":"Abdel-Rahman","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2025.10.019_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202002054","article-title":"Engineering macrophages for cancer immunotherapy and drug delivery","volume":"32","author":"Xia","year":"2020","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib60","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/eji.201444612","article-title":"Innate IFN-\u03b3 promotes development of experimental autoimmune encephalomyelitis: a role for NK cells and M1 macrophages","volume":"44","author":"Dungan","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib61","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","article-title":"New insights into M1\/M2 macrophages: key modulators in cancer progression","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.apsb.2025.10.019_bib62","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/tropicalmed8050276","article-title":"Leishmaniasis: immune cells crosstalk in macrophage polarization","volume":"8","author":"Almeida","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.apsb.2025.10.019_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202401685","article-title":"Imaging identifies superior inflammation targeting of M1 macrophages for cryo-shocked cell pulmonary drug delivery to treat acute lung injury","volume":"13","author":"Wang","year":"2024","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib64","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1021\/acsnano.2c08834","article-title":"Spatial-drug-laden protease-activatable M1 macrophage system targets lung metastasis and potentiates antitumor immunity","volume":"17","author":"Xu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.019_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202309038","article-title":"ZIF-8-encapsulated pexidartinib delivery via targeted peptide-modified M1 macrophages attenuates MDSC-mediated immunosuppression in osteosarcoma","volume":"20","author":"Dong","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.10.019_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.583691","article-title":"Roles of macrophages and exosomes in liver diseases","volume":"7","author":"Shen","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.apsb.2025.10.019_bib67","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.1021\/nn402232g","article-title":"Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors","volume":"7","author":"Jang","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.019_bib68","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/pharmaceutics13091493","article-title":"M1 macrophage-derived exosomes loaded with gemcitabine and deferasirox against chemoresistant pancreatic cancer","volume":"13","author":"Zhao","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.019_bib69","article-title":"Functional immune cell-derived exosomes engineered for the trilogy of radiotherapy sensitization","volume":"9","author":"Ma","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2025.10.019_bib70","first-page":"459","article-title":"Macrophage membrane-mediated targeted drug delivery for treatment of spinal cord injury regardless of the macrophage polarization states","volume":"16","author":"Tang","year":"2021","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib71","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.3390\/pharmaceutics15092243","article-title":"M1 macrophage-biomimetic targeted nanoparticles containing oxygen self-supplied enzyme for enhancing the chemotherapy","volume":"15","author":"Zhang","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.019_bib72","doi-asserted-by":"crossref","DOI":"10.1177\/10732748251316604","article-title":"Macrophage polarisation in the tumour microenvironment: recent research advances and therapeutic potential of different macrophage reprogramming","volume":"32","author":"Guo","year":"2025","journal-title":"Cancer Control"},{"key":"10.1016\/j.apsb.2025.10.019_bib73","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1016\/j.biomaterials.2012.02.022","article-title":"Use of macrophages to deliver therapeutic and imaging contrast agents to tumors","volume":"33","author":"Choi","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.019_bib74","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/intimm\/dxae007","article-title":"Reprogramming T-cell metabolism to enhance adoptive cell therapies","volume":"36","author":"Kates","year":"2024","journal-title":"Int Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib75","article-title":"CRISPR\/Cas9 genome editing for tissue-specific in vivo targeting: nanomaterials and translational perspective","volume":"10","author":"Sahel","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2025.10.019_bib76","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.3390\/pharmaceutics15102458","article-title":"Immunoengineering via chimeric antigen receptor-T cell therapy: reprogramming nanodrug delivery","volume":"15","author":"Katopodi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.019_bib77","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.10.019_bib78","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jconrel.2019.12.047","article-title":"Current challenges and emerging opportunities of CAR-T cell therapies","volume":"319","author":"Abreu","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib79","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cancergen.2022.10.003","article-title":"Mesothelin CAR-T cells secreting PD-L1 blocking scFv for pancreatic cancer treatment","volume":"268-269","author":"Wang","year":"2022","journal-title":"Cancer Genet"},{"key":"10.1016\/j.apsb.2025.10.019_bib80","first-page":"422","article-title":"Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles","volume":"34","author":"Yaman","year":"2024","journal-title":"Bioact Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib81","first-page":"52150","article-title":"Genetically engineered cell membrane-coated nanoparticles with high-density customized membrane receptor for high-performance drug lead discovery","volume":"15","author":"Bu","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.10.019_bib82","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41551-023-01048-8","article-title":"Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR","volume":"7","author":"Zhang","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2025.10.019_bib83","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12967-023-04206-3","article-title":"Inhalable CAR-T cell-derived exosomes as paclitaxel carriers for treating lung cancer","volume":"21","author":"Zheng","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.apsb.2025.10.019_bib84","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","article-title":"Engineering the next generation of CAR-NK immunotherapies","volume":"114","author":"Biederst\u00e4dt","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.apsb.2025.10.019_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303605","article-title":"NK cell exhaustion in the tumor microenvironment","volume":"14","author":"Jia","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.734551","article-title":"NK cells in a tug-of-war with cancer: the roles of transcription factors and cytoskeleton","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib87","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jconrel.2023.09.007","article-title":"Navigating chimeric antigen receptor-engineered natural killer cells as drug carriers via three-dimensional mapping of the tumor microenvironment","volume":"362","author":"Huang","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib88","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jconrel.2023.10.007","article-title":"Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy","volume":"363","author":"Tao","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib89","first-page":"450","article-title":"Recent advances in antitumor dendritic cell vaccines","volume":"38","author":"Ge","year":"2023","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.apsb.2025.10.019_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/science.adn9083","article-title":"In vivo dendritic cell reprogramming for cancer immunotherapy","volume":"386","author":"Ascic","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.10.019_bib91","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.ymthe.2020.03.014","article-title":"Targeted metabolic reprogramming to improve the efficacy of oncolytic virus therapy","volume":"28","author":"Kennedy","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2025.10.019_bib92","article-title":"Expression of SIRP\u03b1-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib93","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2025.10.019_bib94","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/0008-5472.CAN-12-3056","article-title":"Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation","volume":"73","author":"Muthana","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.019_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.14","article-title":"Chimeric antigen receptor-engineered T cells as oncolytic virus carriers","volume":"2","author":"VanSeggelen","year":"2015","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.apsb.2025.10.019_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn2231","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14","author":"Evgin","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2025.10.019_bib97","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41587-023-02118-7","article-title":"An oncolytic virus-T cell chimera for cancer immunotherapy","volume":"42","author":"Chen","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.10.019_bib98","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.16825","article-title":"Advances in macrophage and T cell metabolic reprogramming and immunotherapy in the tumor microenvironment","volume":"12","author":"Cheng","year":"2024","journal-title":"PeerJ"},{"key":"10.1016\/j.apsb.2025.10.019_bib99","doi-asserted-by":"crossref","DOI":"10.1177\/10732748251316604","article-title":"Macrophage polarisation in the tumour microenvironment: recent research advances and therapeutic potential of different macrophage reprogramming","volume":"32","author":"Guo","year":"2025","journal-title":"Cancer Control"},{"key":"10.1016\/j.apsb.2025.10.019_bib100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev-chembioeng-092120-092914","article-title":"Engineering next-generation CAR-T cells: overcoming tumor hypoxia and metabolism","volume":"13","author":"Gao","year":"2022","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"10.1016\/j.apsb.2025.10.019_bib101","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/cancers15010117","article-title":"CAR-NK as a rapidly developed and efficient immunotherapeutic strategy against cancer","volume":"15","author":"Wlodarczyk","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2025.10.019_bib102","doi-asserted-by":"crossref","DOI":"10.26599\/FMH.2024.9420025","article-title":"Research progress of microrobots in tumor drug delivery","volume":"1","author":"Wang","year":"2024","journal-title":"Food & Medicine Homology"},{"key":"10.1016\/j.apsb.2025.10.019_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.135608","article-title":"Polypyrrole\/iron-glycol chitosan nanozymes mediate M1 macrophages to enhance the X-ray-triggered photodynamic therapy for bladder cancer by promoting antitumor immunity","volume":"280","author":"Chuang","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2025.10.019_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202403998","article-title":"Biomimetic diselenide-sonosensitizer nanoplatform for enhanced sonodynamic therapy and in situ remodeling immunosuppressive microenvironment via activating innate and adaptive immunotherapy","volume":"14","author":"Xue","year":"2025","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib105","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jconrel.2025.01.051","article-title":"Microneedle patch-involved local therapy synergized with immune checkpoint inhibitor for pre- and post-operative cancer treatment","volume":"379","author":"Yin","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120159","article-title":"Phagocyte-membrane-coated and laser-responsive nanoparticles control primary and metastatic cancer by inducing anti-tumor immunity","volume":"255","author":"Hu","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.019_bib107","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/1061186X.2021.2020798","article-title":"Novel polysaccharide building hybrid nanoparticles: remodelling TAMs to target ER\u03b1-positive breast cancer","volume":"30","author":"Guo","year":"2022","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2025.10.019_bib108","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2025.10.019_bib109","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001097","article-title":"HITM-SURE: hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery","volume":"8","author":"Katz","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.10.019_bib110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","article-title":"Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial","volume":"32","author":"Hiltbrunner","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2025.10.019_bib111","first-page":"624","article-title":"High-affinity mutant Interleukin-13 targeted CAR T cells enhance delivery of clickable biodegradable fluorescent nanoparticles to glioblastoma","volume":"5","author":"Kim","year":"2020","journal-title":"Bioact Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib112","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2318687121","article-title":"Engineered CD4 T cells for in vivo delivery of therapeutic proteins","volume":"121","author":"Radhakrishnan","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.10.019_bib113","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202113341","article-title":"Design, synthesis, and targeted delivery of an immune stimulant that selectively reactivates exhausted CAR T cells","volume":"61","author":"Napoleon","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2025.10.019_bib114","doi-asserted-by":"crossref","first-page":"16770","DOI":"10.1021\/acsnano.3c03456","article-title":"Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy","volume":"17","author":"Zhu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.019_bib115","doi-asserted-by":"crossref","first-page":"16177","DOI":"10.1021\/acsnano.2c04983","article-title":"Tumor-homing and immune-reprogramming cellular nanovesicles for photoacoustic imaging-guided phototriggered precise chemoimmunotherapy","volume":"16","author":"Fan","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.019_bib116","doi-asserted-by":"crossref","first-page":"11749","DOI":"10.1021\/acsnano.3c02592","article-title":"A near-infrared-II fluorescent nanocatalyst for enhanced CAR T cell therapy against solid tumor by immune reprogramming","volume":"17","author":"Li","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.019_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120670","article-title":"In situ poly I:C released from living cell drug nanocarriers for macrophage-mediated antitumor immunotherapy","volume":"269","author":"Zhou","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.019_bib118","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.019_bib119","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/adfm.201701093","article-title":"Ly6Chi monocytes delivering pH-sensitive micelle loading paclitaxel improve targeting therapy of metastatic breast cancer","volume":"27","author":"Lang","year":"2017","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202303963","article-title":"Mnox nanoenzyme armed CAR-NK cells enhance solid tumor immunotherapy by alleviating the immunosuppressive microenvironment","volume":"13","author":"Duan","year":"2024","journal-title":"Adv Healthcare Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib121","doi-asserted-by":"crossref","first-page":"13959","DOI":"10.1021\/acs.jmedchem.4c00753","article-title":"Advancing tumor-targeted chemo-immunotherapy: development of the CAR-M-derived exosome-drug conjugate","volume":"67","author":"Jiang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.10.019_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2025.10.019_bib123","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jconrel.2021.05.033","article-title":"A dual macrophage polarizer conjugate for synergistic melanoma therapy","volume":"335","author":"Sallam","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib124","article-title":"Sodium valproate enhances efficacy of NKG2D CAR-T cells against glioblastoma","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1208870","article-title":"Unveiling the veil of lactate in tumor-associated macrophages: a successful strategy for immunometabolic therapy","volume":"14","author":"Tao","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib126","doi-asserted-by":"crossref","first-page":"11181","DOI":"10.2147\/IJN.S483815","article-title":"Photo-thermally controllable tumor metabolic modulation to assist T cell activation for boosting immunotherapy","volume":"19","author":"Ma","year":"2024","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.10.019_bib127","doi-asserted-by":"crossref","first-page":"8203","DOI":"10.1038\/s41467-024-52500-5","article-title":"Glypican-3-targeted macrophages delivering drug-loaded exosomes offer efficient cytotherapy in mouse models of solid tumours","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.019_bib128","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.10.019_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.05.005","article-title":"Targeting tumors with IL-10 prevents dendritic cell-mediated CD8+ T cell apoptosis","volume":"35","author":"Qiao","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2025.10.019_bib130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.apsb.2021.08.012","article-title":"Pure drug nano-assemblies: a facile carrier-free nanoplatform for efficient cancer therapy","volume":"12","author":"Fu","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.10.019_bib131","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood-2006-03-012534","article-title":"Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery","volume":"108","author":"Dou","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.10.019_bib132","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.21037\/atm-20-695","article-title":"Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: enusage of plasticity","volume":"8","author":"Nadella","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.apsb.2025.10.019_bib133","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.2147\/IJN.S381170","article-title":"M1 macrophage-derived sonoresponsive nanoparticles for sonodynamic anticancer therapy","volume":"17","author":"Chen","year":"2022","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.10.019_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122456","article-title":"Macrophage-derived biomimetic nanoparticles enhanced SDT combined with immunotherapy inhibited tumor growth and metastasis","volume":"305","author":"Chen","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.019_bib135","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s12272-016-0820-y","article-title":"Diverse macrophages polarization in tumor microenvironment","volume":"39","author":"Rhee","year":"2016","journal-title":"Arch Pharm Res (Seoul)"},{"key":"10.1016\/j.apsb.2025.10.019_bib136","article-title":"Development of liposome-loaded macrophages as tumor-targeted drug delivery carriers: impact of macrophage phenotypes on their liposome-loading capacity and tumor-homing potential","volume":"108","author":"Kono","year":"2025","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.apsb.2025.10.019_bib137","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s40820-020-00531-0","article-title":"Nanoparticle-loaded polarized-macrophages for enhanced tumor targeting and cell-chemotherapy","volume":"13","author":"Hou","year":"2020","journal-title":"Nano-Micro Lett"},{"key":"10.1016\/j.apsb.2025.10.019_bib138","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/16078454.2021.1981534","article-title":"Lenalidomide improves the antitumor activity of CAR-T cells directed toward the intracellular Wilms Tumor 1 antigen","volume":"26","author":"Zhang","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.apsb.2025.10.019_bib139","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2147\/IJN.S288636","article-title":"Engineering of neutrophil membrane camouflaging nanoparticles realizes targeted drug delivery for amplified antitumor therapy","volume":"16","author":"Wang","year":"2021","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.10.019_bib140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejpb.2022.07.002","article-title":"Co-delivery of Interleukin-12 and doxorubicin loaded nano-delivery system for enhanced immunotherapy with polarization toward M1-type macrophages","volume":"177","author":"Li","year":"2022","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2025.10.019_bib141","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s11684-020-0746-0","article-title":"Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system","volume":"14","author":"Wang","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.apsb.2025.10.019_bib142","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/pharmaceutics14051068","article-title":"Extracellular vesicles from M1-polarized macrophages combined with hyaluronic acid and a \u03b2-blocker potentiate doxorubicin's antitumor activity by downregulating tumor-associated macrophages in breast cancer","volume":"14","author":"Jorquera-Cordero","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.019_bib143","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12951-024-02575-5","article-title":"Reactive oxygen species\/glutathione dual sensitive nanoparticles with encapsulation of miR155 and curcumin for synergized cancer immunotherapy","volume":"22","author":"Li","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2025.10.019_bib144","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nbt.4181","article-title":"Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery","volume":"36","author":"Tang","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.10.019_bib145","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1039\/D1TB01980E","article-title":"Carboxy-terminal dendrimers with phenylalanine for a pH-sensitive delivery system into immune cells including T cells","volume":"10","author":"Shiba","year":"2022","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.apsb.2025.10.019_bib146","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/acsnano.0c08384","article-title":"Mesoporous silica nanoparticles as pH-responsive carrier for the immune-activating drug resiquimod enhance the local immune response in mice","volume":"15","author":"Wagner","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.019_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112599","article-title":"Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression","volume":"42","author":"Ramirez-Valdez","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2025.10.019_bib148","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3390\/molecules29112436","article-title":"Drug-loaded mesoporous silica nanoparticles enhance antitumor immunotherapy by regulating MDSCs","volume":"29","author":"Xu","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.10.019_bib149","article-title":"Local exosome inhibition potentiates mild photothermal immunotherapy against breast cancer","volume":"12","author":"Chen","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2025.10.019_bib150","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s12951-024-02853-2","article-title":"Double-camouflaged tellurium nanoparticles for enhanced photothermal immunotherapy of tumor","volume":"22","author":"Li","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2025.10.019_bib151","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.2147\/IJN.S258145","article-title":"Chiral active \u03b2-glucan nanoparticles for synergistic delivery of doxorubicin and immune potentiation","volume":"15","author":"Huang","year":"2020","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.10.019_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114394","article-title":"Cell-based drug delivery systems and their in vivo fate","volume":"187","author":"Yang","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.10.019_bib153","doi-asserted-by":"crossref","first-page":"863","DOI":"10.7150\/thno.11852","article-title":"Cell or cell membrane-based drug delivery systems","volume":"5","author":"Tan","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2025.10.019_bib154","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.7150\/thno.99257","article-title":"Theoretical basis, state and challenges of living cell-based drug delivery systems","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2025.10.019_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.624159","article-title":"Endocytic adaptors in cardiovascular disease","volume":"8","author":"Cui","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.apsb.2025.10.019_bib156","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jconrel.2022.12.038","article-title":"Combinatorial physical methods for cellular therapy: towards the future of cellular analysis?.","volume":"353","author":"Chakrabarty","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415827","article-title":"Diverse neutrophil functions in cancer and promising neutrophil-based cancer therapies","volume":"23","author":"Sounbuli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib158","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","article-title":"CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy","volume":"14","author":"Chang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.019_bib159","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1021\/tx050095o","article-title":"A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo","volume":"18","author":"Gardner","year":"2005","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.apsb.2025.10.019_bib160","article-title":"T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib161","doi-asserted-by":"crossref","first-page":"9799","DOI":"10.1021\/acsnano.2c03573","article-title":"Live macrophage-delivered doxorubicin-loaded liposomes effectively treat triple-negative breast cancer","volume":"16","author":"Yang","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.019_bib162","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1016\/j.biomaterials.2012.04.029","article-title":"Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles","volume":"33","author":"Stephan","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.019_bib163","doi-asserted-by":"crossref","first-page":"12323","DOI":"10.2147\/IJN.S481368","article-title":"Artificially modified NK cell-based synergistic immuno-gene-photodynamic therapy for cancer","volume":"19","author":"Wu","year":"2024","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.10.019_bib164","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3390\/pr8121561","article-title":"An overview of exosomes in cancer therapy: a small solution to a big problem","volume":"8","author":"Rodrigues","year":"2020","journal-title":"Processes"},{"key":"10.1016\/j.apsb.2025.10.019_bib165","doi-asserted-by":"crossref","first-page":"17129","DOI":"10.1021\/acsami.3c18569","article-title":"CXCR4-targeted macrophage-derived biomimetic hybrid vesicle nanoplatform for enhanced cancer therapy through codelivery of manganese and doxorubicin","volume":"16","author":"Jang","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2025.10.019_bib166","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/pharmaceutics15010066","article-title":"Engineered exosomes for tumor-targeted drug delivery: a focus on genetic and chemical functionalization","volume":"15","author":"Akbari","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.019_bib167","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202005562","article-title":"Self-activatable photo-extracellular vesicle for synergistic trimodal anticancer therapy","volume":"33","author":"Ding","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib168","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303835","article-title":"Extracellular vesicles-derived hybrid nanoplatforms for amplified CD47 blockade-based cancer immunotherapy","volume":"35","author":"Tang","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.10.019_bib169","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jconrel.2023.08.002","article-title":"Biomembrane nanostructures: multifunctional platform to enhance tumor chemoimmunotherapy via effective drug delivery","volume":"361","author":"Jiang","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113974","article-title":"Biomembrane-based nanostructures for cancer targeting and therapy: from synthetic liposomes to natural biomembranes and membrane-vesicles","volume":"178","author":"Wang","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.10.019_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122872","article-title":"Cannabidiol-loaded biomimetic macrophage membrane vesicles against post-traumatic stress disorder assisted by ultrasound","volume":"637","author":"Li","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2025.10.019_bib172","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1039\/D0CS00152J","article-title":"Cell primitive-based biomimetic functional materials for enhanced cancer therapy","volume":"50","author":"Luo","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.apsb.2025.10.019_bib173","doi-asserted-by":"crossref","first-page":"12817","DOI":"10.2147\/IJN.S487598","article-title":"T lymphocyte-macrophage hybrid membrane-coated biomimetic nanoparticles alleviate myocarditis via suppressing pyroptosis by targeting gene silencing","volume":"19","author":"Xiong","year":"2024","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2025.10.019_bib174","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1002\/smll.201500987","article-title":"Synthesis of nanogels via cell membrane-templated polymerization","volume":"11","author":"Zhang","year":"2015","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.10.019_bib175","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-53906-x","article-title":"A hypoxia-activated and microenvironment-remodeling nanoplatform for multifunctional imaging and potentiated immunotherapy of cancer","volume":"15","author":"Song","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.019_bib176","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1021\/acsnano.4c16329","article-title":"Nitric oxide-producing multiple functional nanoparticle remodeling tumor microenvironment for synergistic photodynamic immunotherapy against hypoxic tumor","volume":"19","author":"Xu","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.019_bib177","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202203825","article-title":"Constructing hypoxia-tolerant and host tumor-enriched aggregation-induced emission photosensitizer for suppressing malignant tumors relapse and metastasis","volume":"18","author":"Cui","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.apsb.2025.10.019_bib178","doi-asserted-by":"crossref","first-page":"15578","DOI":"10.1039\/C8NR05294H","article-title":"A multi-functional macrophage and tumor targeting gene delivery system for the regulation of macrophage polarity and reversal of cancer immunoresistance","volume":"10","author":"He","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2025.10.019_bib179","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","article-title":"Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T-cell infiltration","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.019_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.08.004","article-title":"The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function","volume":"184","author":"Johnson","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.10.019_bib181","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2326-6066.CIR-17-0502","article-title":"CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction","volume":"6","author":"Siriwon","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.apsb.2025.10.019_bib182","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/thno.40291","article-title":"Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment","volume":"10","author":"Ma","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2025.10.019_bib183","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/hum.2008.068","article-title":"Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes","volume":"20","author":"Rabinovich","year":"2009","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2025.10.019_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114840","article-title":"Engineering cells for precision drug delivery: new advances, clinical translation, and emerging strategies","volume":"197","author":"Chao","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.10.019_bib185","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1021\/acs.bioconjchem.8b00856","article-title":"Synthesis and evaluation of pH-sensitive multifunctional lipids for efficient delivery of CRISPR\/Cas9 in gene editing","volume":"30","author":"Sun","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2025.10.019_bib186","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12951-024-02719-7","article-title":"Acidity-activatable dynamic hybrid nanoplatforms derived from extracellular vesicles of M1 macrophages enhance cancer immunotherapy through synergistic triple immunotherapy","volume":"22","author":"Guo","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2025.10.019_bib187","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.xphs.2025.01.010","article-title":"M1 macrophage membrane-coated nickel-arsenic nanocomplex promoting synergistic treatment of hepatocellular carcinoma","volume":"114","author":"Wang","year":"2025","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109340","article-title":"pH- and enzyme-triggered drug release as an important process in the design of anti-tumor drug delivery systems","volume":"118","author":"Cao","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.10.019_bib189","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-22-1031","article-title":"Cancer-associated fibroblasts in inflammation and antitumor immunity","volume":"29","author":"Kennel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.019_bib190","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11684-023-1025-7","article-title":"Metabolic interventions combined with CTLA-4 and PD-1\/PD-L1 blockade for the treatment of tumors: mechanisms and strategies","volume":"17","author":"Liao","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.apsb.2025.10.019_bib191","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fphar.2015.00095","article-title":"Improving the safety of cell therapy with the TK-suicide gene","volume":"6","author":"Greco","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2025.10.019_bib192","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41434-023-00404-2","article-title":"RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells","volume":"30","author":"Bouquet","year":"2023","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2025.10.019_bib193","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2025.10.019_bib194","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.7150\/thno.50928","article-title":"Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes","volume":"11","author":"Han","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2025.10.019_bib195","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.7150\/ijbs.72534","article-title":"Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance","volume":"18","author":"Zhang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib196","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/aps.2015.92","article-title":"Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment","volume":"36","author":"Sun","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2025.10.019_bib197","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.3390\/ijms25084170","article-title":"Car T cells in solid tumors: overcoming obstacles","volume":"25","author":"Rojas-Quintero","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib198","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \u201cdon't eat me\u201d signal of CD47\u2013SIRP\u03b1 in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.apsb.2025.10.019_bib199","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molonc.2010.04.004","article-title":"Histological types of breast cancer: how special are they?.","volume":"4","author":"Weigelt","year":"2010","journal-title":"Mol Oncol"},{"key":"10.1016\/j.apsb.2025.10.019_bib200","article-title":"The therapeutic effect of traditional Chinese medicine on breast cancer through modulation of the Wnt\/\u03b2-catenin signaling pathway","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2025.10.019_bib201","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/HM9.0000000000000074","article-title":"Drug co-administration in the tumor immune microenvironment of Hepatocellular carcinoma","volume":"3","author":"Shao","year":"2023","journal-title":"Acupuncture and Herbal Medicine"},{"key":"10.1016\/j.apsb.2025.10.019_bib202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000547531","article-title":"Beyond CAR-T: the rise of CAR-NK\/T cells for haematological cancer","volume":"24","author":"Noorafrooz","year":"2025","journal-title":"Acta Haematol"},{"key":"10.1016\/j.apsb.2025.10.019_bib203","doi-asserted-by":"crossref","first-page":"11749","DOI":"10.1021\/acsnano.3c02592","article-title":"A near-infrared-II fluorescent nanocatalyst for enhanced CAR T cell therapy against solid tumor by immune reprogramming","volume":"17","author":"Li","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2025.10.019_bib204","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200844","article-title":"STING agonist promotes CAR T cell trafficking and persistence in breast cancer","volume":"218","author":"Xu","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2025.10.019_bib205","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13046-023-02768-0","article-title":"Lysosome blockade induces divergent metabolic programs in macrophages and tumours for cancer immunotherapy","volume":"42","author":"Ma","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.10.019_bib206","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.actbio.2024.07.042","article-title":"Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery","volume":"186","author":"Zhang","year":"2024","journal-title":"Acta Biomater"},{"key":"10.1016\/j.apsb.2025.10.019_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121872","article-title":"Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice","volume":"291","author":"Zhou","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.019_bib208","first-page":"723","article-title":"Limitations and challenges of direct cell reprogramming in vitro and in vivo","volume":"37","author":"Zhang","year":"2022","journal-title":"Histol Histopath"},{"key":"10.1016\/j.apsb.2025.10.019_bib209","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41392-023-01380-0","article-title":"To metabolomics and beyond: a technological portfolio to investigate cancer metabolism","volume":"8","author":"Danzi","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2025.10.019_bib210","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/HM9.0000000000000038","article-title":"Herbal medicine in the treatment of COVID-19 based on the gut\u2013lung axis","volume":"2","author":"He","year":"2022","journal-title":"Acupuncture and Herbal Medicine"},{"key":"10.1016\/j.apsb.2025.10.019_bib211","doi-asserted-by":"crossref","DOI":"10.26599\/FMH.2024.9420016","article-title":"Flavonoid-rich mulberry leaf extract modulate lipid metabolism, antioxidant capacity, and gut microbiota in high-fat diet-induced obesity: potential roles of FGF21 and SOCS2","volume":"1","author":"Liu","year":"2024","journal-title":"Food & Medicine Homology"},{"key":"10.1016\/j.apsb.2025.10.019_bib212","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MOG.0000000000000139","article-title":"The gut microbiome in health and in disease","volume":"31","author":"Shreiner","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.apsb.2025.10.019_bib213","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/2159-8290.CD-17-1134","article-title":"The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression","volume":"8","author":"Pushalkar","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2025.10.019_bib214","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/s41467-024-45357-1","article-title":"Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial","volume":"15","author":"Alves Costa Silva","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.10.019_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.09.019","article-title":"Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment","volume":"184","author":"Lam","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.10.019_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114467","article-title":"Metal complex lipid-based nanoparticles deliver metabolism-regulating lomitapide to overcome CTC immune evasion via activating STING pathway","volume":"203","author":"Fan","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2025.10.019_bib217","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612613","article-title":"The future of precision oncology","volume":"24","author":"Rulten","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156561","article-title":"Cancer energy reprogramming and the immune responses","volume":"177","author":"Yuan","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.apsb.2025.10.019_bib219","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/cancers15071935","article-title":"Empowering the potential of CAR-T cell immunotherapies by epigenetic reprogramming","volume":"15","author":"Alvanou","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2025.10.019_bib220","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122104","article-title":"Regulating T-cell metabolic reprogramming and blocking PD-1 co-promote personalized postoperative autologous nanovaccines","volume":"297","author":"Chang","year":"2023","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.10.019_bib221","article-title":"Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes","volume":"11","author":"Kim","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.10.019_bib222","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1111\/cas.14591","article-title":"Prognostic significance of spatial immune profiles in human solid cancers","volume":"111","author":"Tsujikawa","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib223","article-title":"From multi-omics to visualization and beyond: bridging micro and macro insights in CAR-T cell therapy","volume":"12","author":"Gong","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2025.10.019_bib224","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3390\/pharmaceutics15071916","article-title":"Artificial intelligence in pharmaceutical technology and drug delivery design","volume":"15","author":"Vora","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2025.10.019_bib225","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114974","article-title":"Towards artificial intelligence-enabled extracellular vesicle precision drug delivery","volume":"199","author":"Greenberg","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.10.019_bib226","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s12967-022-03765-1","article-title":"Integration of CRISPR\/Cas9 with artificial intelligence for improved cancer therapeutics","volume":"20","author":"Bhat","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.apsb.2025.10.019_bib227","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212330","article-title":"Insights into the identification of iPSC- and monocyte-derived macrophage-polarizing compounds by AI-fueled cell painting analysis tools","volume":"25","author":"Br\u00fcggenthies","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib228","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111526","article-title":"Liquid biopsy: a new translational diagnostic and monitoring tool for musculoskeletal tumors","volume":"22","author":"Hadjimichael","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib229","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.trecan.2024.07.010","article-title":"Advances in exosomes utilization for clinical applications in cancer","volume":"10","author":"Batista","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.apsb.2025.10.019_bib230","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/cancers13040847","article-title":"Regulation of antitumor immune responses by exosomes derived from tumor and immune cells","volume":"13","author":"Rinc\u00f3n-Riveros","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2025.10.019_bib231","doi-asserted-by":"crossref","first-page":"C779","DOI":"10.1152\/ajpcell.00048.2021","article-title":"Protein biomarkers in breast cancer-derived extracellular vesicles for use in liquid biopsies","volume":"321","author":"Li","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.apsb.2025.10.019_bib232","doi-asserted-by":"crossref","first-page":"9585","DOI":"10.3390\/ijms21249585","article-title":"Multifaceted functions of platelets in cancer: from tumorigenesis to liquid biopsy tool and drug delivery system","volume":"21","author":"Dovizio","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib233","article-title":"Single-cell genomics: catalyst for cell fate engineering","volume":"9","author":"Li","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.apsb.2025.10.019_bib234","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12913-023-10443-5","article-title":"Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study","volume":"24","author":"Cavallo","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.apsb.2025.10.019_bib235","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jconrel.2023.08.023","article-title":"Revolutionizing cancer treatment: the power of cell-based drug delivery systems","volume":"361","author":"Lu","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.10.019_bib236","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.7150\/thno.108875","article-title":"Macrophage membrane-functionalized nanotherapeutics for tumor targeted therapy","volume":"15","author":"Khan","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.apsb.2025.10.019_bib237","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.10.019_bib238","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2147\/DDDT.S96470","article-title":"Drug-loaded erythrocytes: on the road toward marketing approval","volume":"10","author":"Bourgeaux","year":"2016","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.apsb.2025.10.019_bib239","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41551-021-00698-w","article-title":"The evolution of commercial drug delivery technologies","volume":"5","author":"Vargason","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2025.10.019_bib240","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.10.019_bib241","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002194","article-title":"Phase II clinical trial using anti-CD3 \u00d7 anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0\u20132+) metastatic breast cancer","volume":"9","author":"Lum","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2025.10.019_bib242","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11427-016-5024-7","article-title":"Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells","volume":"59","author":"You","year":"2016","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.apsb.2025.10.019_bib243","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/d41573-020-00220-y","article-title":"Exosome-based candidates move into the clinic","volume":"20","author":"Cully","year":"2021","journal-title":"Nat Rev Drug Discov"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525006963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525006963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T17:08:05Z","timestamp":1771520885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525006963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":243,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2211383525006963"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.10.019","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunocyte reprogramming empowers live-cell drug delivery: Mechanistic insights, delivery strategies, and clinical perspectives","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}